Compounds > 9,13-retinoic acid
Page last updated: 2024-08-01 22:54:47

9,13-retinoic acid

Description

9,13-cis-Retinoic acid : no description available [CHeBI]

Cross-References

ID SourceID
PubMed CID6419708
SCHEMBL ID445176
CHEBI ID177281
MeSH IDM0275182

Synonyms (34)

Synonym
unii-tqd8wk9jq2
9,13-di-cis-ra
tqd8wk9jq2 ,
retinoic acid, 9-cis, 13-cis-
9,13-retinoic acid
9-cis,13-cis-retinoic acid
AB01274784-01
(2z,4e,6z,8e)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid
5352-74-9
CHEBI:177281
9,13-cis-retinoic acid
9,13-di-cis-retinoic acid
LMPR01090023
S1379
SCHEMBL445176
(2z,4e,6z,8e)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenoic acid
AB01274784_02
DTXSID10858776
NCGC00386142-01
3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)-(2e,4z,6e,8z)-nonatetraen-1-oate
9-cis,13-cis-retinoate
9,13-cis-retinoic acid anion
9,13-cis-retinoate
9,13-cis-vitamin-a-acid
3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)-(2e,4z,6e,8z)-nonatetraen-1-oic acid
9,13-cis-vitamin-alpha-acid
SW203749-3
(2z,4e,6z,8e)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid
(9-cis,13-cis)-retinoic acid
tretinoin impurity b [ep impurity]
retinoic acid, (9-cis,13-cis)-
retinoic acid, 9-cis,13-cis-
isotretinoin impurity b [ep impurity]
PD011009

Drug Classes (1)

ClassDescription
retinoidOxygenated derivatives of 3,7-dimethyl-1-(2,6,6-trimethylcyclohex-1-enyl)nona-1,3,5,7-tetraene and derivatives thereof.

Bioassays (5)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
ISSN: 2472-5560		Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
ISSN: 1091-6490		Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
ISSN: 1091-6490		Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
ISSN: 1521-0111		A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
ISSN: 1521-0111		A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.

Research

Studies (23)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's5 (21.74)18.2507
2000's8 (34.78)29.6817
2010's8 (34.78)24.3611
2020's2 (8.70)2.80

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (4.17%)5.53%
Reviews1 (4.17%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other22 (91.67%)84.16%
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
N-(4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)nona-2,4,6,8-tetraenamide
0
retinoid00low000000
tazarotene
0
acetylenic compound;
ethyl ester;
pyridines;
retinoid;
thiochromane		keratolytic drug;
prodrug;
teratogenic agent		00low000000
retinoic acid
0
alpha,beta-unsaturated monocarboxylic acid;
retinoid		human metabolite00low000000
acitretin
0
retinoid00low000000
bexarotene
0
benzoic acids;
naphthalenes;
retinoid		antineoplastic agent00low000000
tamibarotene
0
dicarboxylic acid monoamide;
retinoid;
tetralins		antineoplastic agent;
retinoic acid receptor alpha/beta agonist		00low000000
agn 190299
0
monocarboxylic acid;
pyridines;
retinoid;
thiochromane		keratolytic drug;
teratogenic agent		00low000000
3,4-didehydroretinoic acid
0
retinoid;
vitamin A		human xenobiotic metabolite00low000000
retinoyl beta-glucuronide
0
glucuronic acids;
retinoid		human metabolite00low000000
etretinate
0
enoate ester;
ethyl ester;
retinoid		keratolytic drug00low000000
acitretin
0
acitretin;
alpha,beta-unsaturated monocarboxylic acid;
retinoid		keratolytic drug00low000000
fenretinide
0
monocarboxylic acid amide;
retinoid		antineoplastic agent;
antioxidant		00low000000
4-oxoretinol
0
cyclic ketone;
enone;
primary allylic alcohol;
retinoid		antineoplastic agent00low000000
4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid
0
benzoic acids;
naphthalenes;
retinoid		antineoplastic agent;
retinoic acid receptor agonist;
teratogenic agent		00low000000
13,14-dihydroretinoic acid
0
monocarboxylic acid;
retinoid		00low000000
3-hydroxyretinal
0
retinoid00low000000
4-hydroxyretinal
0
enal;
retinoid;
secondary allylic alcohol		marine metabolite00low000000
motretinide
0
retinoid00low000000
vitamin a2
0
retinoid;
vitamin A		human xenobiotic metabolite;
marine xenobiotic metabolite;
mouse metabolite		00low000000
4-oxoretinoic acid
0
enone;
retinoid		human xenobiotic metabolite00low000000
mannosylretinylphosphate
0
retinoid00low000000
4-hydroxyretinoic acid
0
retinoid;
secondary allylic alcohol		human metabolite00low000000
3-hydroxyretinol
0
diol;
retinoid		00low000000
sr 11302
0
alpha,beta-unsaturated monocarboxylic acid;
retinoid;
toluenes		antineoplastic agent;
AP-1 antagonist		00low000000
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
pirinixic acid
1
aryl sulfide;
organochlorine compound;
pyrimidines		2004200420.0low000100
triiodothyronine
1
2-halophenol;
amino acid zwitterion;
iodophenol;
iodothyronine		human metabolite;
mouse metabolite;
thyroid hormone		2006200618.0low000100
bexarotene
2
benzoic acids;
naphthalenes;
retinoid		antineoplastic agent201420197.5low000020
imatinib mesylate
1
methanesulfonate saltanticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
tyrosine kinase inhibitor		2002200222.0low000100
tretinoin
20
retinoic acid;
vitamin A		anti-inflammatory agent;
antineoplastic agent;
antioxidant;
AP-1 antagonist;
human metabolite;
keratolytic drug;
retinoic acid receptor agonist;
retinoid X receptor agonist;
signalling molecule		1997201918.2high108570
alitretinoin
7
retinoic acidantineoplastic agent;
keratolytic drug;
metabolite;
retinoid X receptor agonist		1997201717.3medium103130
bromochloroacetic acid
1
2-bromocarboxylic acid;
monocarboxylic acid;
organochlorine compound		2000200024.0low001000
isotretinoin
4
retinoic acidantineoplastic agent;
keratolytic drug;
teratogenic agent		1997201913.0low001030
fenretinide
1
monocarboxylic acid amide;
retinoid		antineoplastic agent;
antioxidant		201920195.0low000010
triphenyltin
1
2012201212.0low000010
bucladesine
1
3',5'-cyclic purine nucleotide201520159.0low000010
transforming growth factor beta
2
1997199926.0low002000
ConditionIndicatedStudiesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
Acute Confusional Senile Dementia0
1
2014201410.0low000010
Alzheimer Disease0
1
2014201410.0low000010
Breast Cancer0
1
2002200222.0low000100
Breast Neoplasms0
1
2002200222.0low000100
Cancer of Lung0
1
2002200222.0low000100
Cancer of Ovary0
1
2002200222.0low000100
Cancer of Pituitary0
1
2006200618.0low000100
Cancer of Prostate0
1
201720177.0low000010
Cancer of Stomach0
1
2000200024.0low001000
Chronic Disease0
1
2008200816.0low100100
Chronic Illness0
1
2008200816.0low100100
Cirrhoses, Experimental Liver0
1
1999199925.0low001000
Congenital Zika Syndrome0
1
202020204.0low000010
Dermatitis, Eczematous0
1
2008200816.0low100100
Diabetes Mellitus, Adult-Onset0
1
2004200420.0low000100
Diabetes Mellitus, Type 20
1
2004200420.0low000100
Disease Models, Animal0
1
202020204.0low000010
Eczema0
1
2008200816.0low100100
Granulocytic Leukemia, Chronic0
1
2002200222.0low000100
Hand Dermatoses0
1
2008200816.0low100100
Hand Dermatosis0
1
2008200816.0low100100
Hyperglycemia0
1
2003200321.0low000100
Hyperglycemia, Postprandial0
1
2003200321.0low000100
Leukemia, Myelogenous, Chronic, BCR-ABL Positive0
1
2002200222.0low000100
Lung Neoplasms0
1
2002200222.0low000100
Neoplasms, Nervous System0
1
201920195.0low000010
Neuroblastoma0
1
201920195.0low000010
Ovarian Neoplasms0
1
2002200222.0low000100
Pituitary Neoplasms0
1
2006200618.0low000100
Prostatic Neoplasms0
1
201720177.0low000010
Stomach Neoplasms0
1
2000200024.0low001000
Zika Virus Infection0
1
202020204.0low000010

Safety/Toxicity (1)

ArticleYear
Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial.
The British journal of dermatology, , Volume: 158, Issue:4		2008

Long-term Use (1)

ArticleYear
Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial.
The British journal of dermatology, , Volume: 158, Issue:4		2008

Bioavailability (1)

ArticleYear
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Molecular pharmacology, , Volume: 96, Issue:5		2019